Related Experiment Video
Updated: Jan 20, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Recurrent uterine adenofibroma revealed to be hyperparathyroidism-jaw tumor syndrome: Case report
Go Nakai1, Takashi Yamada2, Tomohito Tanaka3
1Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki City, Osaka 569-8686, Japan.
Abstract:
Uterine adenofibroma was previously classified as a benign mixed epithelial and mesenchymal tumor, but the WHO removed it from its fifth edition due to diagnostic overlap with low-grade adenosarcoma or benign polyps. We report a case of a 21-year-old woman with a recurrent uterine polypoid tumor initially diagnosed as adenofibroma on biopsy and resected multiple times. MRI revealed heterogeneous intrauterine masses with cystic changes, and PET-CT showed weak FDG uptake. Eventually, hysterectomy confirmed adenofibroma. She also had a prior diagnosis of primary hyperparathyroidism caused by parathyroid adenoma. Due to the early onset and recurrent uterine tumors, hyperparathyroidism-jaw tumor syndrome (HPT-JT) was suspected. Immunohistochemistry showed loss of parafibromin expression in the uterine tumor, supporting the diagnosis. This case highlights the importance of considering genetic syndromes such as HPT-JT in young patients with recurrent uterine tumors, enabling appropriate surveillance for associated neoplasms in the parathyroid, jaw, and kidneys.
Related Concept Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
10:04Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models
08:55Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
Uterine Tubes
14:11Building Finite Element Models to Investigate Zebrafish Jaw Biomechanics
Enhancing Drug Delivery in Recurrent Glioblastoma with Laser-Induced Hyperthermia

